News
Podcast
Episode 94: The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease
Author(s):
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive commentary from Alberto J. Espay, MD, PhD, and Anton P. Porsteinsson, MD. [LISTEN TIME: 48 minutes]
Anton P. Porsteinsson, MD
Alberto J. Espay, MD, PhD
Episode 94 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 94, "The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease," features an in-depth dive into the recent approval of lecanemab (Leqembi; Eisai) for Alzheimer disease and the ongoing debate about its potential benefit, the amyloid-targeting class of medicines, and the communication of data. Featured in this episode is commentary from 2 experts in neurology clinical care: Anton P. Porsteinsson, MD, the William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine, and the director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester School of Medicine and Dentistry; and Alberto Espay, MD, PhD, the division director and Research Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, and a professor of clinical neurology and rehabilitation medicine at the University of Cincinnati.
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com
EPISODE BREAKDOWN
- 1:45 – Introduction and main findings
- 3:15 – Espay, with his perspective on the downstream effects of the approval
- 10:10 – Porsteinsson, with his perspective on the downstream effects of the approval
- 18:30 – Secondary end points and safety data
- 20:05 – Porsteinsson, on the recent progress in AD
- 23:05 – Espay, on contextualizing the effect of amyloid clearance
- 26:00 – Porsteinsson, on the logistics of the approval
- 34:20 – Espay, on the lingering unanswered questions
- 38:20 – Espay, on the communication of data to the public around the amyloid therapies
- 42:25 – Porsteinsson, on how things evolve going forward
The stories and studies featured in this week's show, as well as additional expert interviews on lecanemab, can be found here:
Show notes:
Additional reading and coverage:
- FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease
- Medicare Expands Coverage for Fully Approved Alzheimer Agent Lecanemab
- Lecanemab to be Tested in Preclinical Alzheimer Disease
- Therapeutics Aim at Modifying Alzheimer Disease
Additional expert interviews:
- David Bates, PhD: Downstream Impacts of Lecanemab on Alzheimer Disease, Future Drug Development
- Howard Fillit, MD: Lecanemab’s Impact on Care and Diagnosis and the Future of Alzheimer Disease Treatment
- Nicole Fowler, PhD, MHSA: Preparing Primary Care Centers for New Wave of Alzheimer Agents
- Ronald C. Petersen, MD, PhD: Lessons Learned About Clinically Meaningful Benefit from Antiamyloid Trials
- Sharon Cohen, MD, FRCPC: Significance of Expanding Antiamyloid Therapy Class, Toolbox to Treat Alzheimer
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below:
